Physician pricing and health insurance reimbursement
نویسندگان
چکیده
This study was based on physician claims records from three Blue Shield Plans. The principal results are: • Physicians are income-motivated. This means that income incentives can be incorporated into reimbursement systems to achieve specific ends, and that care should be taken to assure that new mechanisms do not create income incentives for physicians to act contrary to policy objectives. • Physician pricing is reasonably competitive. • Physicians do not discriminate in price in their private lines of business, but they appear to discriminate between Medicare and the private lines. Allowance caps in the minor lines of business have no appreciable impact on charge levels or the rate of charge inflation. • The Economic Stabilization Program significantly slowed the growth rate of Medicare charges, but had no discernible effect on the inflation rate of private charges. This indicates that allowance controls applied to a large part, but not all, of physicians' business induce physicians to "shift costs" against patients insured by programs where allowances are not controlled. • The tests conducted indicate that pursuit of a target net income is not a pervasive characteristic of physicians' economic goal behavior. Therefore, reimbursement controls on utilization to counteract demand inducement are not justified at this time. However, in view of the large increase in physician supply expected over the next decade, the issue of demand inducement merits continued monitoring. • Physicians are significantly more likely to participate in Plans' eligible business when allowances are high rather than low. Physicians of low-perceived quality are also significantly more likely to participate than physicians of high-perceived quality. Since increases in allowances raise insurance benefit costs, it follows
منابع مشابه
مقایسه نظام قیمت گذاری و بیمه دارو در ایران و کشورهای منتخب
Introduction: Pharmaceuticals comprise a large portion of health care expenditures, including insurance organizations expenditures. Accumulated evidence suggests that the inefficiencies of Iran's health insurance structure have led to soaring out- of- pocket payments by the beneficiaries of health insurance organizations. This study was conducted to compare pricing and reimbursement of pharmace...
متن کاملبررسی پوشش بیمهای دارو در ایران در مقایسه با کشورهای منتخب
Introduction: in Iran, the compilation council of drug, having an advisory role, is responsible to cover medicine costs for health insurances. Health Insurance High Council also acts as the final decision maker about the admission of new drugs. This article studies how new drugs in Iran's health insurances are covered compared with some selected countries. Methods: After collecting drug accep...
متن کاملThe impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
Background Over 10 years after the establishment of the National Health Insurance Scheme (NHIS) in Ghana, the use of a median pricing methodology for pharmaceuticals remains a topic of debate due to its positive and negative outcomes. Residual effects of this pricing methodology include proliferation of low-quality medicines, irrational medicine use, insurance fraud and other untoward outcomes....
متن کاملMarketplace Plans With Narrow Physician Networks Feature Lower Monthly Premiums Than Plans With Larger Networks.
The introduction of health insurance Marketplaces under the Affordable Care Act has been associated with growth of restricted provider networks. The value of this plan design strategy, including its association with lower premiums, is uncertain. We used data from all silver plans offered in the 2014 health insurance exchanges in the fifty states and the District of Columbia to estimate the asso...
متن کاملSelecting the acceptance criteria of medicines in the reimbursement list of public health insurance of Iran, using the “Borda”method: a pilot study
Decision-making for medicines to be accepted in Iran’s public health insurance reimbursement list is a complex process and involves factors, which should be considered in applying a coverage for medicine costs. These processes and factors are not wholly assessed, while assessment of these factors is an essential need for getting a transparent and evidence-based approach toward medicine reimburs...
متن کامل